Loading
In 232 Swedish early triple-negative cancers, half were PD-L1-positive by the atezolizumab test (SP142 IC 1%) but only 27% by the pembrolizumab threshold (22C3 CPS 10), and the two tests picked partly different patients.
PD-L1 by SP142 immune-cell score and 22C3 combined positive score was compared in 232 early-stage TNBC patients from the population-based SCAN-B cohort. Positivity was 50.9% for SP142 IC 1% or more, 27.2% for 22C3 CPS 10 or more, 53.9% for CPS 1 or more and 41.8% for 22C3 IC 1% or more. Concordance between SP142 IC-positive and the three 22C3 scores was 73.7% (kappa 0.48), 81.5% (0.63) and 86.6% (0.73). CD274 mRNA correlated with every scoring (Spearman 0.59 to 0.62). PD-L1 positivity and TILs were favourable prognostic factors in chemotherapy-treated patients, strongest for CPS 10 and distant relapse-free interval (HR 0.18), but PD-L1 was not independent of TILs.
This is the population-based prevalence for the two label thresholds in early TNBC, and it shows the KEYNOTE-355 CPS 10 gate would admit only about a quarter of unselected patients.
Shares PD-L1 IC score (immune-cell score, SP142), VENTANA PD-L1 (SP142) Assay, KEYNOTE-355, PD-L1 IHC 22C3 pharmDx.
Shares KEYNOTE-355, Combined positive score (CPS), Tumour-infiltrating lymphocytes (TILs), PD-L1.
Shares KEYNOTE-355, Combined positive score (CPS), Tumour-infiltrating lymphocytes (TILs), PD-L1.
Shares VENTANA PD-L1 (SP142) Assay, KEYNOTE-355, Combined positive score (CPS), Immunohistochemistry (IHC).
Shares KEYNOTE-355, Combined positive score (CPS), PD-L1, Triple-negative breast cancer (TNBC).
Shares PD-L1 IC score (immune-cell score, SP142), PD-L1 IHC 22C3 pharmDx, PD-L1 CPS (combined positive score), Immunohistochemistry (IHC).
Shares KEYNOTE-355, PD-L1 IHC 22C3 pharmDx, PD-L1 CPS (combined positive score).
Shares KEYNOTE-355, PD-L1 CPS (combined positive score), PD-L1, Pembrolizumab.